Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
reductase/enflamasyon
Bağlantı panoya kaydedilir
Sayfa 1 itibaren 41 Sonuçlar
Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
The present invention relates to the combination of certain known therapeutic compounds for therapeutic purposes. The substances used in the combinations according to the invention are known active agents from the phosphodiesterase 4 (PDE4) inhibitor class and active agents from the
Combination method of treating acne using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
The present invention is directed to a combination method for treating ache using selective 5.alpha.-reductase 1 inhibitors, 5.alpha.-reductase 2 inhibitors, combinations thereof, or dual inhibitors, including but not limited to:
Sepiapterin reductase inhibitors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
Tetrahydrobiopterin (BH4) is an enzyme cofactor for various aromatic amino acid hydroxylases, including phenylalanine, tyrosine and tryptophan hydroxylases, as well as being an important cofactor for other enzymes such as the nitric oxide synthases (inducible NOS (iNOS), endothelial NOS
Methods involving aldose reductase inhibitors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
I. Field of the Invention
Embodiments of this invention are related generally to physiology and medicine. More specifically, this invention is related to aldose reductase inhibitors (ARIs) and their use in treating and ameliorating inflammation.
II. Background
Aldose
Methods involving aldose reductase inhibitors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
I. Field of the Invention
Embodiments of this invention are related generally to physiology and medicine. More specifically, this invention is related to aldose reductase inhibitors (ARIs) and their use in treating and ameliorating inflammation.
II. Background
Aldose
Methods involving aldose reductase inhibitors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
I. Field of the Invention
Embodiments of this invention are related generally to physiology and medicine. More specifically, this invention is related to aldose reductase inhibitors (ARIs) and their use in treating and ameliorating inflammation.
II. Background
Aldose
Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
The pro-inflammatory cytokines, such as tumor necrosis factor-.alpha. (TNF-.alpha.) and interleukin-1.beta. (IL-1.beta.), contribute to the pathogenesis of various allergic, inflammatory and autoimmune diseases. Consequently, multiple therapeutic approaches have been aimed at reducing the
Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
The pro-inflammatory cytokines, such as tumor necrosis factor-.alpha. (TNF-.alpha.) and interleukin-1.beta. (IL-1.beta.), contribute to the pathogenesis of various allergic, inflammatory and autoimmune diseases. Consequently, multiple therapeutic approaches have been aimed at reducing the
Sepiapterin reductase inhibitors for the treatment of pain
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
In general, the present invention relates to small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and to the medical use of these compounds.
Tetrahydrobiopterin (BH4), which has the following structure,
##STR00001## is an essential cofactor of
Sepiapterin reductase inhibitors for the treatment of pain
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
In general, the present invention relates to small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and to the medical use of these compounds.
Tetrahydrobiopterin (BH4), which has the following structure,
##STR00001## is an essential cofactor of
Materials and methods for inhibiting mamalian S-nitrosoglutathione reductase
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
Various aspects and embodiments relate generally to materials and methods for inhibiting the enzyme S-nitrosoglutathione reductase (GSNOR) and for diagnosing, studying and treating various conditions and diseases related to the activity of this enzyme.
BACKGROUND
S-nitrosylation of
Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF RELATED ART
1. Technical Field
The present disclosure relates to the treatment of cancer. More particularly, the disclosed invention relates to the use of novel bi-functional inhibitors against histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Pharmaceutical composition and method for inhibiting inflammation
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
This application claims priority to Taiwan Patent Application No. 099137186 filed on Oct. 29, 2010.
FIELD
The present invention relates to a pharmaceutical composition for inhibiting inflammation, especially to a pharmaceutical composition useful for arthritis.
BACKGROUND
Arthritis is a common
Metabolically inert anti-inflammatory and anti-tumor antifolates
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF INVENTION
This invention relates to folic acid antagonists that are metabolically inert exhibiting a high level of anti-inflammatory and anti-tumor activity. Metabolically inert classical antifolates are new and therefore they exhibit unexpected biological properties such as those recited
Heterocyclic amine-boranes, and method of inhibiting DNA topoisomerase activity and/or combatting inflammation, hyperlipidemia, and/or neoplasia using amine-borane compounds
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to amine-borane compounds, including novel heterocyclic amine-boranes, and to a method of inhibiting enzyme (e.g., DNA topoisomerase) activity and/or combatting inflammation, hypolipidemia and/or neoplasia using
Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı
- 55 dilde çalışır
- Bilim destekli bitkisel kürler
- Görüntüye göre bitki tanıma
- Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
- Aramanızla ilgili bilimsel yayınları okuyun
- Şifalı bitkileri etkilerine göre arayın
- İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın
Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır
